Literature DB >> 15737890

LPI-labile plasma iron in iron overload.

Z Ioav Cabantchik1, William Breuer, G Zanninelli, P Cianciulli.   

Abstract

Labile plasma iron (LPI) represents a component of non-transferrin-bound iron (NTBI) that is both redox-active and chelatable, capable of permeating into organs and inducing tissue iron overload. It appears in various types of hemosiderosis (transfusional and non-transfusional) and in other iron-overload conditions. Sustained levels of LPI could over time compromise organ (e.g. heart) function and patient survival. With the advent of methods for measuring LPI in the clinical setting, it has become possible to assess the implications of LPI in the management of iron overload based on regimens of iron chelation. As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737890     DOI: 10.1016/j.beha.2004.10.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  68 in total

1.  Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.

Authors:  Yesim Aydinok; Patricia Evans; Chantal Y Manz; John B Porter
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Authors:  Hussam Ghoti; Eitan Fibach; Drorit Merkel; Galit Perez-Avraham; Sigal Grisariu; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 3.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

4.  Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Authors:  Vip Viprakasit; Norbert Gattermann; Jong Wook Lee; John B Porter; Ali T Taher; Dany Habr; Nicolas Martin; Gabor Domokos; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-07-12       Impact factor: 3.443

5.  Reproductive capacity in iron overloaded women with thalassemia major.

Authors:  Sylvia T Singer; Elliott P Vichinsky; Ginny Gildengorin; Jereon van Disseldorp; Mitchell Rosen; Marcelle I Cedars
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

6.  Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia.

Authors:  Gianluca Abbati; Federica Incerti; Chiara Boarini; Francesca Pileri; Davide Bocchi; Paolo Ventura; Elena Buzzetti; Antonello Pietrangelo
Journal:  Intern Emerg Med       Date:  2018-11-29       Impact factor: 3.397

7.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

8.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

9.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

10.  Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

Authors:  Shahina Daar; Anil Pathare; Hanspeter Nick; Ulrike Kriemler-Krahn; Abdel Hmissi; Dany Habr; Ali Taher
Journal:  Eur J Haematol       Date:  2008-12-22       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.